2025 acc/aha hypertension guideline
1 paper1 finding
- 1 lab in 1 country
- Humans1
Outcomes
1Antihypertensive pharmacotherapy recommendation
upin humans1
1 study
Antihypertensive pharmacotherapy recommendation
upin humans1
2025 acc/aha hypertension guideline increases antihypertensive pharmacotherapy recommendation in humans (13.84% (95% CI, 7.06%-20.63%)).
“13.84% (95% CI, 7.06%-20.63%) of untreated adults eligible under the Predicting Risk of Cardiovascular Disease Events threshold (0.42 million) became newly eligible for pharmacotherapy”
Humansuntreated stage 1 hypertensionn = 1,926
Journal of the American Heart Association10 Oct 2026
Latest
1 in 12 monthsJournal of the American Heart Association
Guideline-Directed Treatment Eligibility and Burden of Untreated Stage-1 Hypertension Under the 2025 American College of Cardiology/American Heart Association Hypertension Guideline: Insights From NHANES 2015 to 2020
Cross-sectional study of 1,926 peopleIndustry & policy